ARWR

Equibles Rating blended score · not investment advice

Overall

Buy

Technical · trend & momentum Strong Buy

◦ 50 / 200-day cross no cross

+ Price vs 200-day avg +39% above

+ Price vs 50-day avg +10% above

◦ RSI (14) 64 · neutral

+ MACD trend positive

+ 52-week position 99% · near high

Sentiment · smart money Bullish

◦ Trend (MA cross) 50d $76 › 200d $60 — 50d above 200d

+ Institutional flow 3 of 442 funds reported for Jun 30 · net +162 sh shares

− Insider flow Net -$1.9M over 90 days · 100% sells

+ Short interest 8.33% of float · ▼ -5.3% MoM · 8.2 days cover

◦ Volume signal Volume near normal

+ Institution breadth 442 holders — near 3-yr high, broad support

Fundamentals Strong

− Revenue growth −49% Y/Y

+ EPS growth +100% Y/Y

+ Free cash flow $156.9M

+ Balance sheet net cash $184.4M

Blended from price, positioning & fundamentals · daily-close · not investment advice.

Up next

Next earnings call

Aug 4, 2026 Est · unconfirmed · in 4 wks

FQ4-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 7, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Technicals

trend & momentum for long-term holders Strong Buy

0 · 2 · 4

50 / 200-day cross

no cross Neutral

Price vs 200-day avg

+39% above Bullish

Price vs 50-day avg

+10% above Bullish

RSI (14)

64 · neutral Neutral

MACD trend

positive Bullish

52-week position

99% · near high Bullish

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $76 › 200d $60 — 50d above 200d

Institutional flow Accumulating

3 of 442 funds reported for Jun 30 · net +162 sh shares

Insider flow Distributing

Net -$1.9M over 90 days · 100% sells

Short interest Falling

8.33% of float · ▼ -5.3% MoM · 8.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

442 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $14 Now $84 · 99% 52-wk high $85

vs 200-day avg +39% vs 50-day avg +10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
New written prescriptions per week	30	currently averaging	—
Patients who have received at least one pre-filled syringe shipment	180	since launch through May 7, 2026	—
Total prescriptions received and in process to date	400	since launch through May 7, 2026	—
prescriptions from patients naive to the APOC3 class	85%	fiscal second quarter ending March 31, 2026 call	—
REDEMPLO U.S. wholesale acquisition cost (WAC)	$45,000	fiscal second quarter ending March 31, 2026 call	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ARWR Arrowhead Pharmaceuticals, Inc. this stock	$11.83B	+26.5%	-48.6%	—	8.3%
AKTX Akari Therapeutics Plc	$953.21B	-9.9%	—	—	0.0%
ONC BeOne Medicines Ltd.	$470.30B	-2.0%	+22179.2%	957.1	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$134.02B	+16.5%	+46.2%	31.3	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$69.80B	-15.1%	+20.8%	16.3	3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

442

% held: 82.4%
Reported: 3 of 442
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

444

View

Short & Settlement

Short Interest Falling

Shares short

11.7M

Days to cover: 8.2d
Change: -652.7K sh

View

Short Volume

Short vol %

43%

As of: Jul 2, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $521
As of: Jun 12, 2026

View

Off-Exchange

Off-exchange %

47.2%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$1.9M

Buyers / Sellers: 0 / 3

Buyers Sellers

View

Congressional Trades Sell

Member

Daniel Goldman

Amount: $1.0K–$15.0K
Traded: Jan 31, 2023

View

Financials

Revenue (FY)

$829.4M

Net income (FY): $-1.6M
EPS diluted: $-0.01

View

Filings

SEC Filings

Latest

8-K

Filed: Jun 16, 2026
This year: 12

View

Proposed Sales

Value

$641.9K

Shares: 10.0K
Filed: Mar 5, 2026

View

Earnings & Events

Earnings Calls

Last call

Jun 10, 2026

View

Performance

	5D	20D	120D	MTD	YTD
ARWR	+6.0%	+15.8%	+29.2%	+3.0%	+26.5%
SPY	+1.4%	-1.3%	+8.0%	-0.3%	+9.2%
vs SPY	+4.5%	+17.0%	+21.2%	+3.3%	+17.3%

Price & Indicators

Technicals

Key metrics

Versus peers

At a glance

Performance